Diabetes mellitus and cardiovascular disease

European Journal of Internal Medicine

Volumn 13, Issue 1, 2002, Pages 15-30

  Wagner A M ^a   Martinez Rubio A ^a   Ordoez Llanos J ^a   Perez Perez A ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Cardiovascular disease; Diabetes mellitus; Secondary prevention; Treatment

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; SIMVASTATIN; STREPTOKINASE; VERAPAMIL; WARFARIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; FIBRINOLYSIS; HEART INFARCTION; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE; MORTALITY; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; REVASCULARIZATION; REVIEW; SECONDARY PREVENTION;

EID: 0036172631     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(01)00194-7     Document Type: Review

References (242)

1. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association
2. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95783 individuals followed for 12.4 years
3. Epidemiology of macrovascular disease in diabetes
4. Diabetes mellitus and cardiovascular disease in women
5. Sex differences in the impact of coexistent diabetes with coronary heart disease
6. Coronary artery disease in IDDM. Gender differences in risk factors but not risk
7. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
8. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
9. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation
10. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
11. Physical activity, dyspnea, and chest pain before and after coronary artery bypass grafting in relation to a history of diabetes
12. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty
13. Diabetics with coronary disease have a prevalence of asymptomatic aschemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of nondiabetic patients: an ACIP database
14. Coronary stenting in diabetics: immediate and mid-term clinical outcome
15. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
16. Prevention of the angioplastic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
17. Rationale, design and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT)
18. Management of dyslipidemia in adults with diabetes
19. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
20. Diabetes is a risk factor for sudden death
21. Type 2 diabetes and acute myocardial infarction. Angiographic findings and results of an invasive therapeutic approach in type 2 diabetic versus nondiabetic patients
22. Coronary angioplasty in diabetic patients. The National Heart, Lung and Blood Institute Percutaneous Transluminal Angioplasty registry
23. Clinical predictors of morbidity and mortality in patients with myocardial infarction or revascularization who underwent cardiac rehabilitation, and importance of diabetes and exercise capacity
24. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction
25. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis
26. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus
27. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment?
28. Clinical studies on diabetic myocardial disease using exercise testing with myocardial scintigraphy and endomyocardial biopsy
29. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease?
30. Diabetes mellitus and hypertension
31. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for myocardial infarction: the GUSTO-I experience
32. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents
33. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome
34. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIB angioplasty substudy
35. The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia
36. Mechanism and time course of S-T and T-Q segment changes during acute regional myocardial ischemia in the pig heart determined by extracellular and intracellular recordings
37. Sequence and magnitude of ventricular volume changes in painful and painless myocardial ischemia
38. Electrophysiological changes and ventricular arrhythmias in the early phase of regional myocardial ischemia
39. Definition, pathogenesis and classification of unstable angina
40. Significance of silent myocardial ischemia during exercise testing in patients with coronary artery disease
41. Prognostic importance of myocardial ischemia detected by ambulatory monitoring in patients with stable coronary artery disease
42. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction
43. Prognostic implications of myocardial ischemia during daily life in low risk patients with coronary artery disease
44. Detection of ambulatory ischemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study
45. Silent myocardial ischemia and infarction: insights from the Framingham study
46. Unrecognized myocardial infarction: five-year incidence, mortality and risk factors
47. High incidence of silent myocardial ischaemia in elderly patients with non insulin-dependent diabetes mellitus
48. Silent myocardial ischemia in patients with non-insulin-dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography
49. Prevalence and prediction of ischaemia in diabetes mellitus: a population-based study
50. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus
51. Asymptomatic transient ST changes during ambulatory ECG monitoring in diabetic patients
52. Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population
53. Frequency of painless myocardial ischemia during exercise tolerance testing in patients with and without diabetes mellitus
54. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy
55. Alterations in postural and Valsalva responses in coronary heart disease
56. Impaired vagal heart rate control in coronary artery disease
57. Reduction in sudden deaths and coronary mortality in myocardial infarction patients after rehabilitation. 15 year follow-up study
58. Effects of intensified lifestyle modification on the need for further revascularization after coronary angioplasty
59. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes
60. Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men
61. A randomized, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics
62. Habitual physical activity, aerobic capacity and metabolic control in patients with newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus: effect of 1-year diet and exercise intervention
63. Effect of physical exercise on lipoprotein (a) and low-density lipoprotein modifications in type 1 and type 2 diabetic patients
64. Intentional weight loss and mortality among overweight individuals with diabetes
65. Metoprolol in acute myocardial infarction (MIAMI): a randomised placebo-controlled international trial
66. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction
67. Effect of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: retrospective data of two large studies
68. Timolol treatment after myocardial infarction in diabetic patients
69. Diabetic patients and beta-blockers after acute myocardial infarction
70. The effect of pindolol on the two year mortality after complicated myocardial infarction
71. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial
72. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease
73. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction
74. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high risk patients
75. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy
76. Effect of metoprolol on the counter-regulation and recognition of prolonged hypoglycemia in insulin-dependent diabetics
77. Effect of cardioselective and nonselective β-blockade on the hypoglycemic response in insulin dependent diabetes
78. Excess mortality associated with diuretic therapy in diabetes mellitus
79. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2
80. Effect of diuretic treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
81. A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction
82. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
83. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
84. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
85. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial
86. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
87. Uniformity of captopril benefit in the SAVE study: subgroup analysis
88. Angiotensin-converting-enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation study
89. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
90. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial
91. The risk of myocardial infarction associated with antihypertensive drug therapies
92. Nifedipine: dose-related increase in mortality in patients with coronary heart disease
93. Effects of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT II)
94. Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study in Stockholm (APSIS)
95. The effect of diltiazem on mortality and reinfarction after myocardial infarction
96. Long-term mortality follow-up of hospital survivors of a myocardial infarction randomized to nifedipine in the SPRINT study. Secondary Prevention Reinfarction Israeli Nifedipine Trial
97. Calcium antagonists in patients with coronary artery disease: a cohort study of 11575 patients
98. Calcium channel blockers and mortality in elderly patients with myocardial infarction
99. The effect of verapamil on left ventricular remodelling and diastolic function after acute myocardial infarction (the Verapamil Infarction Study on Remodelling and Relaxation-VISOR)
100. Early administration of verapamil after thrombolysis in acute anterior myocardial infarction. Effect on left ventricular remodeling and clinical outcome. VAMI Study Group. Verapamil Acute Myocardial Infarction
101. Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complications Trial
102. Aspirin therapy in diabetes. Position statement
103. Aspirin therapy in diabetes. Technical review
104. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
105. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14
106. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease
107. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses of the Scandinavian Simvastatin Survival Study
108. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
109. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels
110. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS
111. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
112. The effect of aggressive lowering of low-density lipoprotein cholesterol and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
113. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes. The Post Coronary Artery Bypass Graft Trial
114. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
115. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
116. Cardiovascular outcomes in type 2 diabetes
117. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
118. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention study
119. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group
120. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study: a randomized study
121. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up
122. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B
123. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview
124. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart
125. Factors modifying ischemic injury in the isolated rat heart
126. Importance of free fatty acids as a determinant of myocardial oxygen consumption in myocardial ischemic injury during norepinephrine infusion in dogs
127. Prospective randomized trial of glucose-insulin-potassium in acute myocardial infarction
128. Clinical effects of glucose-insulin-potassium on left ventricular function in acute myocardial infarction. Results from a randomized clinical trial
129. Enhancement of left ventricular function by glucose-insulin-potassium infusion in treatment of myocardial infarction
130. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo-controlled trials
131. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year
132. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction
133. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2
134. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients
135. Retinal haemorrhage after thrombolytic therapy
136. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial
137. Selection bias in the use of thrombolytic therapy in acute myocardial infarction
138. Use of reperfusion therapy for acute myocardial infarction in the United States. Data from the National Registry of Myocardial Infarction 2
139. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis Myocardial Infarction (TIMI) Trial, Phase II
140. Direct angioplasty in acute myocardial infarction. State of the art and current controversies
141. Does primary angioplasty improve prognosis of patients with diabetes and acute myocardial infarction?
142. Direct infarct intervention in the diabetic: does it really work?
143. Clinical and angiographic determinants of primary angioplasty success
144. Restenosis rates in diabetic patients. A comparison of coronary stenting and balloon angioplasty in native coronary vessels
145. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
146. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease
147. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
148. Coronary angioplasty with or without stent implantation for acute myocardial infarction
149. Improved clinical outcome after widespread use of coronary-artery stenting in Canada
150. Comparación de la evolución clínica y angiográfica de pacientes diabéticos y no diabéticos tratados con angioplastia convencional frente a implantación de stent en arterias coronarias nativas
151. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study
152. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus
153. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
154. Eight-year mortality in the Emory Angioplasty versus Surgery Trial
155. Seven-year outcome in the bypass angioplasty revascularization investigation (BARI) by treatment and diabetic status
156. The effect of previous coronary artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction
157. Diabetes and heart transplantation
158. Heart transplantation in diabetic patients
159. Influence on survival after heart transplantation of contraindications seen in transplant recipients
160. Heart transplantation in patients with diabetic end-organ damage before transplantation
161. Mid-term results of heart transplantation in diabetic patients
162. Long-term results in diabetic patients undergoing heart transplantation
163. Cardiac transplantation in diabetic patients
164. Heart transplantation in diabetic patients
165. Diabetes mellitus as a risk factor for death from stroke: prospective study of the middle-aged Finnish population
166. Diabetes and the risk of stroke: The Honolulu Heart Program
167. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study
168. Risk factors for death from different types of stroke: Multiple Risk Factor Intervention Trial Research Group
169. Risk factors and 20-year stroke mortality in men and women in the Renfrew/Paisley study in Scotland
170. Risk factors for early death in acute ischemic stroke and intracerebral hemorrhage
171. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects
172. Prognosis after stroke in diabetic patients: a controlled prospective study
173. Epidemiology and costs of acute hospital care for cerebrovascular disease in diabetic and nondiabetic populations
174. Cardiovascular disease in diabetes mellitus
175. Ischemic stroke subtypes. A population-based study of incidence and risk factors
176. Blood glucose, glycosylated haemoglobin and outcome of ischemic brain infarction
177. The prognostic value of blood glucose in patients with acute stroke
178. Effect of diabetes mellitus and blood glucose on the size of cerebral infarction and causes of death: neuropathological study of 77 cases of infarction in the sylvian artery area
179. Cerebrovascular disease: diabetes and cerebral atherosclerosis
180. A comparative study of cerebral atherosclerosis in males and females
181. Diabetes and cerebrovascular accidents
182. Stroke in patients with diabetes: the Copenhagen Stroke Study
183. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus
184. Stroke recurrence within 2 years after ischemic infarction
185. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975-1989
186. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study
187. The natural history of stroke in diabetic patients
188. Clinical characteristics in diabetic stroke patients
189. The haematocrit value in diabetic patients with ischaemic stroke
190. A long-term follow-up study of Japanese diabetic patients: mortality and causes of death
191. Diabetes and change in cognitive function
192. Is diabetes associated with cognitive impairment and cognitive decline among older women?
193. Decreased cognitive function in aging non-insulin-dependent patients
194. Risk of dementia among persons with diabetes mellitus: a population-based cohort study
195. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial
196. European stroke prevention study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke
197. Determinants of carotid intima media thickness: a population based ultrasonography study in eastern Finnish men
198. Carotid artery disease in NIDDM
199. Risk factors for extracranial internal or common carotid artery disease in persons 60 years and older
200. Prevalence of carotid atherosclerosis in diabetic patients: ultrasound high-resolution B-mode imaging on carotid arteries
201. Morbidity, mortality and albuminuria in type 2 diabetic patients: a three-year prospective study of a random cohort in general practice
202. Early cerebral complications in carotid endarterectomy: risk factors
203. Risk factors for amputation in patients with diabetes mellitus
204. A prospective study of risk factors for diabetic foot ulcer
205. Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy and foot ulcers
206. Infrainguinal reconstruction in diabetes
207. Increased arterial stiffness and thickness in medium sized arteries in patients with insulin dependent diabetes mellitus
208. Investigating the capillary circulation with 99mTc-macroaggregated albumin: a prospective study in patients with diabetes and foot ulceration
209. Trends in the care of the diabetic foot. Expanded role of arterial reconstruction
210. Arterial reconstruction in arteriopathic diabetic perforating ulcer - is it effective? Revascularization in diabetes mellitus and peripheral arterial occlusive disease
211. A flexible approach to infrapopliteal vein grafts in patients with diabetes mellitus
212. The use of arm vein in lower-extremity revascularization: results of 520 procedures performed in eight years
213. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure
214. Long-term results of arterial allograft below-knee bypass grafts for limb salvage: a retrospective multicenter study
215. Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI)
216. Mortality over a period of 10 years in patients with peripheral arterial disease
217. MRC/BHF Heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience
218. The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
219. Heterogeneous nature of renal lesions in type II diabetes
220. Diabetic patients on renal replacement therapy: analysis of Catalan Registry data
221. Diabetic nephropathy in type II diabetes
222. Prevalence of renal artery stenosis in diabetes mellitus - an autopsy study
223. Prevalence of renal artery stenosis in subjects with type 2 diabetes and coexistent hypertension
224. The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy?
225. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere
226. Fatal outcome factors of intestinal infarct of primary vascular origin
227. Magnitude and determinants of coronary artery disease in juvenile-onset insulin-dependent diabetes mellitus
228. Prognosis of diabetic with diabetes onset before the age of thirty-one
229. Cardiovascular disease in insulin dependent diabetes mellitus: similar rates but different risk factors in the US compared with Europe
230. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors
231. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus
232. Prognostic significance off microalbuminuria in insulin-dependent diabetes mellitus. A twenty-three year follow-up
233. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patient with insulin dependent diabetes
234. Are predictors of coronary heart disease in type 1 diabetes the same? A prospective study
235. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy
236. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis
237. Factor contributing to deaths of diabetics under fifty years of age
238. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients
239. Global burden of diabetes, 1995-2025, prevalence, numerical estimates and projections